IPSOS reported that the PD-L1 inhibitor, atezolizumab, showed significantly improved efficacy over single-agent chemotherapy when used as first-line treatment for patients with NSCLC, who were not suitable for platinum-containing two-agent chemotherapy due to physical status score 2–3 or comorbidities and contraindications to chemotherapy (28). Here, CD274 is linked to non-small cell lung carcinoma.